Get Your Personalized Supplement StackSupplement Stack Quiz

OTHER GROWTH FACTORS

Q: Are growth factors safe as supplements?

Growth factors can be safe when used under medical supervision, especially for specific conditions like wound healing. However, some, like FGF23, can increase risk markers, necessitating careful consideration and monitoring.

Q: Do growth factors promote cancer?

While some growth factors are targeted by cancer therapies (e.g., VEGFR inhibitors to inhibit tumor growth), inappropriate or prolonged use of certain growth factors could theoretically promote cell proliferation, raising concerns about tumorigenic potential.

Q: How quickly do growth factors work?

The time frame for effects varies. For wound healing, benefits can often be observed within weeks of consistent application. For other applications, the timeline depends on the specific growth factor and its intended therapeutic goal.

Q: Can growth factors be taken orally?

Generally, growth factors are not effective when taken orally due to their protein nature, which makes them susceptible to degradation in the digestive system. Topical or injectable routes are typically preferred for better efficacy.

Also known as: Fibroblast Growth Factors (FGFs), Vascular Endothelial Growth Factors (VEGFs), Insulin-like Growth Factors (IGFs), Wound Healing Factors, Cytokines, Growth Factors

Overview

Growth factors are a broad class of naturally occurring proteins and peptides that play crucial roles in regulating cellular growth, proliferation, differentiation, and repair. Produced endogenously by various cells and tissues, they act as signaling molecules, binding to specific receptors on target cells to initiate biological responses. In clinical and supplement contexts, they are primarily utilized for their ability to promote tissue repair and regeneration, and in some cases, to modulate metabolic or cardiovascular health. While some growth factors, like those used in wound healing, show clear therapeutic benefits, others, such as FGF23, can serve as risk markers, particularly in conditions like kidney or heart failure. The research on growth factors is moderate to advanced, with numerous clinical trials and meta-analyses evaluating their efficacy in specific conditions, highlighting their diverse applications and varying levels of evidence.

Benefits

Growth factors offer several evidence-based benefits, primarily in tissue repair and regeneration. Topical application of various growth factors has been shown to significantly improve wound healing outcomes, as evidenced by a meta-analysis of 51 randomized controlled trials (RCTs), though effect sizes vary depending on the specific factor and wound type. In oncology, Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors, a class of compounds targeting growth factor pathways, have demonstrated high rates of disease stabilization in recurrent or metastatic adenoid cystic carcinoma (ACC), indicating their efficacy in cancer treatment. However, it's important to note that some growth factors can also be indicators of risk; for instance, vitamin D supplementation (doses >2000 IU/day) can increase circulating levels of Fibroblast Growth Factor 23 (FGF23) by approximately 21 pg/ml, which is considered a cardiovascular risk marker, especially in patients with end-stage kidney or heart failure. Insulin-like Growth Factor-1 (IGF-1) has been identified as an elevated biomarker in Parkinson’s disease patients, suggesting a diagnostic role rather than a direct therapeutic benefit. Benefits are particularly relevant for patients with chronic wounds, certain cancers (like ACC), and those with kidney or heart failure where FGF23 levels are monitored.

How it works

Growth factors exert their effects by binding to specific cell surface receptors, such as tyrosine kinase receptors, on target cells. This binding initiates a cascade of intracellular signaling events that ultimately regulate gene expression, leading to changes in cell proliferation, migration, and survival. Different growth factors interact with specific receptors (e.g., FGF receptors, VEGF receptors, IGF receptors) and consequently influence various body systems, including the skin, vascular endothelium, kidneys, heart, and nervous system. Their mechanism involves modulating cellular processes essential for tissue development, maintenance, and repair. Due to their protein nature, oral bioavailability is generally poor, as they are susceptible to degradation in the digestive tract, making topical or intravenous administration more common in clinical settings.

Side effects

The safety profile of growth factors varies significantly depending on the specific type and application. Generally, when used appropriately, they are considered safe. Common side effects, particularly with topical applications, include local irritation at the site of administration. Systemic effects are more dependent on the specific growth factor and dosage. For instance, elevated levels of Fibroblast Growth Factor 23 (FGF23), which can be influenced by high-dose vitamin D supplementation, are associated with potential cardiovascular effects and are considered a cardiovascular risk marker, especially in patients with pre-existing kidney or heart failure. Uncommon side effects (1-5%) may include more pronounced systemic responses related to their biological activity. Rare side effects (<1%) include a theoretical concern regarding tumorigenic potential with prolonged or inappropriate use, given their role in cell proliferation. Drug interactions are possible, particularly with immunosuppressants or certain cancer therapies. Contraindications include caution in patients with active cancer or significant cardiovascular disease. Special consideration and monitoring are required for patients with kidney or heart failure due to the potential for FGF23 elevation.

Dosage

Dosage guidelines for 'other growth factors' are highly variable and depend on the specific growth factor, the condition being treated, and the route of administration. There is no single standardized dosage for all growth factors. For example, the effect of vitamin D on FGF23 levels has been observed with doses exceeding 2000 IU/day. In clinical settings, optimal dosage ranges are determined through specific clinical trials for each growth factor and indication. The maximum safe dose is also highly dependent on the individual factor and the patient's overall health status. Timing considerations vary; for instance, wound healing applications may require repeated topical administration. Due to their protein nature, oral bioavailability is generally poor, limiting their effectiveness when taken orally. Therefore, topical applications for localized effects (e.g., wound healing) or injectable forms for systemic effects are typically preferred. The efficacy of some growth factors, like FGF23, can be influenced by cofactors such as vitamin D.

FAQs

Are growth factors safe as supplements?

Growth factors can be safe when used under medical supervision, especially for specific conditions like wound healing. However, some, like FGF23, can increase risk markers, necessitating careful consideration and monitoring.

Do growth factors promote cancer?

While some growth factors are targeted by cancer therapies (e.g., VEGFR inhibitors to inhibit tumor growth), inappropriate or prolonged use of certain growth factors could theoretically promote cell proliferation, raising concerns about tumorigenic potential.

How quickly do growth factors work?

The time frame for effects varies. For wound healing, benefits can often be observed within weeks of consistent application. For other applications, the timeline depends on the specific growth factor and its intended therapeutic goal.

Can growth factors be taken orally?

Generally, growth factors are not effective when taken orally due to their protein nature, which makes them susceptible to degradation in the digestive system. Topical or injectable routes are typically preferred for better efficacy.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/32855522/ – This systematic review and meta-analysis of 23 RCTs found that vitamin D supplementation, particularly doses over 2000 IU/day, significantly increased FGF23 levels, a cardiovascular risk marker, especially in patients with kidney or heart failure. The study highlights the need for caution when supplementing with high doses of vitamin D in vulnerable populations.
https://journals.lww.com/plasreconsurg/fulltext/2015/10001/wound_growth_factors_meta_analysis___do_they_work_.224.aspx – This meta-analysis of 51 RCTs and large retrospective studies concluded that topical growth factors improve wound healing outcomes. The study emphasizes that the efficacy varies depending on the specific growth factor and the type of wound, suggesting a targeted approach is beneficial.
https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2819420 – This systematic review and meta-analysis of 17 prospective trials demonstrated that VEGFR inhibitors, such as lenvatinib and axitinib, achieve high rates of disease stabilization in patients with recurrent or metastatic adenoid cystic carcinoma (ACC). The findings support the inclusion of these inhibitors in ACC treatment guidelines.
https://www.neurology.org/doi/10.1212/WNL.98.18_supplement.2832 – This meta-analysis of 14 observational studies identified elevated serum IGF-1 levels in Parkinson’s disease patients compared to controls. The study suggests IGF-1's potential as a biomarker for Parkinson's disease, rather than indicating a direct therapeutic benefit.